Netherlands vs Reunion: Prostate cancer death rate in men
Netherlands
14.6 deaths per 100,000 people
in 2023
Reunion
14.14 deaths per 100,000 people
in 2016
Netherlands rank
43rd
Reunion rank
44th
Prostate cancer death rate in men over time
- Netherlands
- Reunion
How they compare
Netherlands currently reports 14.6 deaths per 100,000 people against 14.14 deaths per 100,000 people in Reunion, a difference of 0.46 deaths per 100,000 people.
The two have swapped places 8 times across 16 shared years of data; in 2001 it was Netherlands ahead.
Netherlands ranks 43rd and Reunion ranks 44th of 111 countries.
Netherlands has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Netherlands | Reunion | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 19.96 deaths per 100,000 people | 19.41 deaths per 100,000 people | 0.5478 deaths per 100,000 people | Netherlands |
| 2010s | 16.64 deaths per 100,000 people | 15.59 deaths per 100,000 people | 1.05 deaths per 100,000 people | Netherlands |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher prostate cancer death rate in men, Netherlands or Reunion?
- Netherlands, at 14.6 deaths per 100,000 people against 14.14 deaths per 100,000 people in Reunion as of 2023.
- What is the difference in prostate cancer death rate in men between Netherlands and Reunion?
- 0.46 deaths per 100,000 people, with Netherlands ahead.
- How many years of comparable data are there for Netherlands and Reunion?
- 16 years are reported by both, from 2001 to 2016.
- How do Netherlands and Reunion rank globally for prostate cancer death rate in men?
- Netherlands ranks 43rd and Reunion ranks 44th of 111 countries.
- Where does this data come from?
- WHO Mortality Database (2025) β with minor processing by Our World in Data, published as Prostate cancer death rate in men. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Reported deaths from prostate cancer in males in those aged all ages per 100,000 people.